3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
83
Lung Neoplasms
29
Neoplasms
7
Neoplasm Metastasis
7
Carcinoma
5
Colorectal Neoplasms
4
NSCLC
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Non Small Cell Lung Cancer Metastatic
2
Multiple Myeloma
2
Meningeal Carcinomatosis
2
Lymphoma
2
Hematologic Neoplasms
2
Head and Neck Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stage II-IIIB Non-small Cell Lung Carcinoma
1
Stage IB-IIIA Non-small Cell Lung Carcinoma
1
Solid Tumor, Adult
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Interventions
Carboplatin
46
Etoposide
45
durvalumab
28
atezolizumab
26
Cisplatin
21
Topotecan
19
pembrolizumab
16
PM 01183
15
Nivolumab
12
Specimen Handling
11
Drug Therapy
10
anlotinib
9
Radiotherapy
9
Paclitaxel
9
Temozolomide
8
Magnetic Resonance Spectroscopy
8
AMG 757
8
Radiosurgery
7
Platinum
7
Irinotecan
7
toripalimab
6
olaparib
6
Biopsy
6
Ipilimumab
5
Injections
5
Docetaxel
5
Bevacizumab
5
trilaciclib
4
tremelimumab
4
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
osimertinib
×
1 year
×
Clear all
NCT07153055
2025-12-18
LOTS
Indiana University
Phase 1/2
Not yet recruiting
16 enrolled